BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 25749719)

  • 1. The RUNX1-PU.1 axis in the control of hematopoiesis.
    Imperato MR; Cauchy P; Obier N; Bonifer C
    Int J Hematol; 2015 Apr; 101(4):319-29. PubMed ID: 25749719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis.
    Huang G; Zhang P; Hirai H; Elf S; Yan X; Chen Z; Koschmieder S; Okuno Y; Dayaram T; Growney JD; Shivdasani RA; Gilliland DG; Speck NA; Nimer SD; Tenen DG
    Nat Genet; 2008 Jan; 40(1):51-60. PubMed ID: 17994017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia.
    Diffner E; Beck D; Gudgin E; Thoms JA; Knezevic K; Pridans C; Foster S; Goode D; Lim WK; Boelen L; Metzeler KH; Micklem G; Bohlander SK; Buske C; Burnett A; Ottersbach K; Vassiliou GS; Olivier J; Wong JW; Göttgens B; Huntly BJ; Pimanda JE
    Blood; 2013 Mar; 121(12):2289-300. PubMed ID: 23327922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subnuclear targeting of Runx1 is required for synergistic activation of the myeloid specific M-CSF receptor promoter by PU.1.
    Li X; Vradii D; Gutierrez S; Lian JB; van Wijnen AJ; Stein JL; Stein GS; Javed A
    J Cell Biochem; 2005 Nov; 96(4):795-809. PubMed ID: 16149049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinatorial action of RUNX1 and PU.1 in the regulation of hematopoiesis.
    Saunthararajah Y; Boccuni P; Nucifora G
    Crit Rev Eukaryot Gene Expr; 2006; 16(2):183-92. PubMed ID: 16749897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pin1-mediated prolyl isomerization of Runx1 affects PU.1 expression in pre-monocytes.
    Islam R; Yoon WJ; Woo KM; Baek JH; Ryoo HM
    J Cell Physiol; 2014 Apr; 229(4):443-52. PubMed ID: 24037986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations.
    Huang G; Zhao X; Wang L; Elf S; Xu H; Zhao X; Sashida G; Zhang Y; Liu Y; Lee J; Menendez S; Yang Y; Yan X; Zhang P; Tenen DG; Osato M; Hsieh JJ; Nimer SD
    Blood; 2011 Dec; 118(25):6544-52. PubMed ID: 22012064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Pu.1 locus is differentially regulated at the level of chromatin structure and noncoding transcription by alternate mechanisms at distinct developmental stages of hematopoiesis.
    Hoogenkamp M; Krysinska H; Ingram R; Huang G; Barlow R; Clarke D; Ebralidze A; Zhang P; Tagoh H; Cockerill PN; Tenen DG; Bonifer C
    Mol Cell Biol; 2007 Nov; 27(21):7425-38. PubMed ID: 17785440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy.
    Gu X; Hu Z; Ebrahem Q; Crabb JS; Mahfouz RZ; Radivoyevitch T; Crabb JW; Saunthararajah Y
    J Biol Chem; 2014 May; 289(21):14881-95. PubMed ID: 24695740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter.
    van der Kouwe E; Heller G; Czibere A; Pulikkan JA; Agreiter C; Castilla LH; Delwel R; Di Ruscio A; Ebralidze AK; Forte M; Grebien F; Heyes E; Kazianka L; Klinger J; Kornauth C; Le T; Lind K; Barbosa IAM; Pemovska T; Pichler A; Schmolke AS; Schweicker CM; Sill H; Sperr WR; Spittler A; Surapally S; Trinh BQ; Valent P; Vanura K; Welner RS; Zuber J; Tenen DG; Staber PB
    Blood; 2021 Oct; 138(15):1345-1358. PubMed ID: 34010414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of Notch-1 expression decreases PU.1-mediated myeloid differentiation signaling in acute myeloid leukemia.
    Chen PM; Yen CC; Wang WS; Lin YJ; Chu CJ; Chiou TJ; Liu JH; Yang MH
    Int J Oncol; 2008 Jun; 32(6):1335-41. PubMed ID: 18497996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PU.1: a crucial and versatile player in hematopoiesis and leukemia.
    Kastner P; Chan S
    Int J Biochem Cell Biol; 2008; 40(1):22-7. PubMed ID: 17374502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The +37 kb Cebpa Enhancer Is Critical for Cebpa Myeloid Gene Expression and Contains Functional Sites that Bind SCL, GATA2, C/EBPα, PU.1, and Additional Ets Factors.
    Cooper S; Guo H; Friedman AD
    PLoS One; 2015; 10(5):e0126385. PubMed ID: 25938608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia.
    Bluteau D; Gilles L; Hilpert M; Antony-Debré I; James C; Debili N; Camara-Clayette V; Wagner-Ballon O; Cordette-Lagarde V; Robert T; Ripoche H; Gonin P; Swierczek S; Prchal J; Vainchenker W; Favier R; Raslova H
    Blood; 2011 Dec; 118(24):6310-20. PubMed ID: 21725049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helicase-like transcription factor is a RUNX1 target whose downregulation promotes genomic instability and correlates with complex cytogenetic features in acute myeloid leukemia.
    Cheng CK; Chan NP; Wan TS; Lam LY; Cheung CH; Wong TH; Ip RK; Wong RS; Ng MH
    Haematologica; 2016 Apr; 101(4):448-57. PubMed ID: 26802049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
    Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ordered acquisition of Class II and Class I mutations directs formation of human t(8;21) acute myelogenous leukemia stem cell.
    Shima T; Miyamoto T; Kikushige Y; Yuda J; Tochigi T; Yoshimoto G; Kato K; Takenaka K; Iwasaki H; Mizuno S; Goto N; Akashi K
    Exp Hematol; 2014 Nov; 42(11):955-65.e1-5. PubMed ID: 25101977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A role for RUNX1 in hematopoiesis and myeloid leukemia.
    Ichikawa M; Yoshimi A; Nakagawa M; Nishimoto N; Watanabe-Okochi N; Kurokawa M
    Int J Hematol; 2013 Jun; 97(6):726-34. PubMed ID: 23613270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of concentration-dependent functions of PU.1 in hematopoiesis using mouse models.
    DeKoter RP; Kamath MB; Houston IB
    Blood Cells Mol Dis; 2007; 39(3):316-20. PubMed ID: 17629523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.